VolitionRx stock edges lower as investors weigh Lind financing and recent trading range

VolitionRx stock (ISIN US92852X1037) remains in penny-stock territory in early September 2026, with recent market data showing the shares changing hands at 0.43 USD as of September 1, 2026 according to a technical snapshot, while a separate closing reference still points to 0.78 USD as of August 7, 2026.

Recent price levels and trading range

According to an overview of VolitionRx trading signals dated September 1, 2026, the stock last traded at 0.43 USD on Nasdaq, highlighting how far it has moved below the dollar mark and underlining the speculative nature of the name at current levels.

A separate price summary compiled from closing data indicates that VolitionRx closed at 0.78 USD on August 7, 2026, so the more recent 0.43 USD snapshot implies a decline of 0.35 USD over that span, which is a drop of about 44.9 percent and reflects increased selling pressure in late summer 2026.

Financing overhang from Lind-linked registration

The pressure on VolitionRx stock coincides with renewed attention on a previously filed shelf registration that lines up new VolitionRx shares for resale in connection with a financing arrangement with Lind, as summarized in a Form S-3 description that highlights how additional equity could come to market and dilute existing holders over time.

In that Form S-3 overview, the Lind note deal is described as allowing VolitionRx to register shares that can be sold into the market, which means investors have to factor in a potential increase in the free float and in the company’s fully diluted share count once the securities covered by the registration are issued or resold.

Business focus on blood-based cancer diagnostics

VolitionRx focuses on developing blood-based diagnostic tests that analyze nucleosomes, with the aim of detecting cancer and other diseases from a simple blood draw rather than invasive procedures, a business model that gives the company significant upside potential if it can translate its technology into commercial adoption.

VolitionRx stock on Nasdaq remains volatile

VolitionRx stock is listed on Nasdaq in the United States under the ticker VNRX, and the recent indication of 0.43 USD as of September 1, 2026 illustrates how volatility and financing-related dilution concerns continue to shape trading, leaving the stock firmly in speculative territory for investors who follow small-cap diagnostics names.